What is the mechanism of action of pyrimethamine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mechanism of Action of Pyrimethamine

Primary Mechanism

Pyrimethamine is a folic acid antagonist that selectively inhibits dihydrofolate reductase (DHFR) in parasites, blocking the synthesis of nucleic acid precursors required for parasite growth and replication. 1

Detailed Pharmacologic Action

  • Pyrimethamine acts as a competitive inhibitor of the DHFR enzyme, which is part of the bifunctional dihydrofolate reductase-thymidylate synthase (DHFR-TS) enzyme complex in parasites like Toxoplasma gondii and Plasmodium species. 1, 2

  • The drug's therapeutic selectivity is based on differential requirements between host and parasite for nucleic acid precursors involved in growth, with highly selective activity against Toxoplasma gondii. 1

  • By inhibiting DHFR, pyrimethamine prevents the reduction of dihydrofolate to tetrahydrofolate, which is essential for one-carbon transfer reactions necessary for purine and pyrimidine synthesis. 2

Synergistic Effects

  • The action of pyrimethamine against Toxoplasma gondii is greatly enhanced when used in conjunction with sulfonamides, which block an earlier step in the folate synthesis pathway. 1

  • This synergistic combination effectively prevents severe disease in experimental models, as demonstrated in toxoplasmic uveitis studies where the dual therapy prevented development of severe ocular disease. 1

Clinical Pharmacology

  • Pyrimethamine is well absorbed orally with peak plasma levels occurring between 2 to 6 hours following administration. 1

  • The drug has a prolonged plasma half-life of approximately 96 hours and is 87% bound to human plasma proteins, which explains why leucovorin must be continued for at least 1 week after the last pyrimethamine dose in poisoning cases. 1, 3

Resistance Mechanisms

  • Resistance to pyrimethamine occurs through point mutations in the DHFR domain, most commonly at residue 108 (S108N), with additional mutations at positions C59R, N51I, and I164L conferring progressively greater resistance. 4, 5

  • These mutations cause structural changes that reduce pyrimethamine binding affinity while maintaining enzyme function, leading to Ki values increasing from 1.5 nM in wild-type to 859 nM in quadruple-mutant forms. 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.